has function has role immunizes against disease immunizes recipient lung cancer Homo sapiens recombinant vector vaccine therapeutic vaccine function peptide vaccine vaccine in clinical trial role recombinant vector vaccine role peptide vaccine role recombinant viral vector vaccine lung cancer vaccine Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine Oliver He PMID:29661145 25003478 Virginia He Jimmy Guo NCT: https://clinicaltrials.gov/ct2/show/NCT00516685 Jie Zheng 5190 A peptide vaccine preparation, containing recombinant human epidermal growth factor (rEGF) linked to the Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51, with potential active immunotherapy activity. Recombinant human EGF-rP64K/Montanide ISA 51 vaccine may trigger a humoral immune response against vaccine rEGF and rP64K and, so, against endogenous EGF. Antibody-mediated inhibition of endogenous EGF binding to its receptor, epithelial growth factor receptor (EGFR), may result in the inhibition of tumor cell proliferation. cancer vaccine VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=5190 Gene name: LV28_RS26095 transcriptional regulator RegF NCI: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C70674 therapeutic cancer vaccine